Imperial College London

Rigetti Computing Awarded Innovate UK Grant to Develop Quantum Machine Learning Techniques for Financial Data Streams

Retrieved on: 
Thursday, January 11, 2024
Standard Chartered, Rigetti Computing, Machine learning, Imperial College London, University, Standard, Amazon Web Services, Imperial, Area studies, Map, Algorithm, Digital, Innovation, Software, AWS, HPC, NISQ

LONDON, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Rigetti UK Limited, a wholly owned subsidiary of Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, today announced that it was awarded an Innovate UK grant as part of the Feasibility Studies in Quantum Computing Applications competition.

Key Points: 
  • LONDON, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Rigetti UK Limited, a wholly owned subsidiary of Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, today announced that it was awarded an Innovate UK grant as part of the Feasibility Studies in Quantum Computing Applications competition.
  • The consortium aims to use quantum computing to improve current classical machine learning techniques used by financial institutions to analyze complex data streams.
  • Classical machine learning techniques used to assist and provide insights to these services have limitations as these data streams are, in general, complex.
  • Combining quantum computing with classical machine learning methodology could offer more powerful resources for processing these data streams, given the potential for quantum computers to process some types of information more efficiently than with classical resources alone.

L.E.K. Consulting Announces 11 New Global Partner Promotions

Retrieved on: 
Tuesday, January 9, 2024
Master of Engineering, ChromeOS, Stanford University, Biochemistry, School, Wellesley College, Imperial College London, London Business School, Master of Research, Tuck School of Business, Emlyon Business School, Health care, Mathematics, Commerce, Bell, Tuchman, University, Business, Consumer, Hydrogen, Digital, Babson College, Global education, Environment, Dartmouth College, Recycling, MBA, Bachelor of Science, Medtech, King's College London, Doctor of Philosophy, Pharma, St. Stephen's College, Master of Science, Mechanical engineering, L.E.K. Consulting, Construction, Organization, College, Queen's University, Education, Nataraja, Timm, Management

Consulting has elected 11 new partners.

Key Points: 
  • Consulting has elected 11 new partners.
  • The promotions recognize the significant expertise and insights that these leaders bring to bear for clients across multiple industry sectors and geographies who are facing critical decisions.
  • "We are pleased to announce the newest partner appointments at L.E.K.
  • With gratitude and pride, we congratulate them on this accomplishment and look forward to their continued impact and contributions to both our clients and our firm," said Clay Heskett, Global Manager Partner at L.E.K.

Robin AI Raises $26 million as Legal Sector Embraces AI

Retrieved on: 
Wednesday, January 3, 2024
Venture round, Work, Microsoft, Ecosystem, Imperial College London, Private law, Research, PwC, Heart, LLM, Temasek, PepsiCo, Clifford Chance, AI, Lawyer, Microsoft Word, Yum, Traction, Machine learning, Negotiation, Medical device

LONDON and NEW YORK, Jan. 2, 2024 /PRNewswire/ -- As demand for generative AI in the legal sector explodes, Robin AI, the AI-powered legal copilot, today announces that it has raised $26 million in new funding. The Series B round is led by Temasek, a global investment company headquartered in Singapore. Other investors include QuantumLight, Plural and AFG Partners.

Key Points: 
  • Brands
    Investment will be used to accelerate US expansion, launch in Asia Pacific and hire more AI engineers
    LONDON and NEW YORK, Jan. 2, 2024 /PRNewswire/ -- As demand for generative AI in the legal sector explodes, Robin AI, the AI-powered legal copilot, today announces that it has raised $26 million in new funding.
  • Robin AI was founded in 2019 by Richard Robinson, a lawyer at Clifford Chance, and James Clough, a machine learning research scientist at Imperial College.
  • Robin AI places quality and accuracy at the heart of its approach.
  • We are building the AI platform for the legal sector - a service that deeply understands every aspect of the legal function, from drafting contracts, researching case law to explaining legal concepts - our AI will help people tackle every legal task.

Robin AI Raises $26 million as Legal Sector Embraces AI

Retrieved on: 
Wednesday, January 3, 2024
Venture round, Work, Microsoft, Ecosystem, Imperial College London, Private law, Research, PwC, Heart, LLM, Temasek, PepsiCo, Clifford Chance, AI, Lawyer, Microsoft Word, Yum, Traction, Machine learning, Negotiation, Medical device

LONDON and NEW YORK, Jan. 2, 2024 /PRNewswire/ -- As demand for generative AI in the legal sector explodes, Robin AI, the AI-powered legal copilot, today announces that it has raised $26 million in new funding. The Series B round is led by Temasek, a global investment company headquartered in Singapore. Other investors include QuantumLight, Plural and AFG Partners.

Key Points: 
  • Brands
    Investment will be used to accelerate US expansion, launch in Asia Pacific and hire more AI engineers
    LONDON and NEW YORK, Jan. 2, 2024 /PRNewswire/ -- As demand for generative AI in the legal sector explodes, Robin AI, the AI-powered legal copilot, today announces that it has raised $26 million in new funding.
  • Robin AI was founded in 2019 by Richard Robinson, a lawyer at Clifford Chance, and James Clough, a machine learning research scientist at Imperial College.
  • Robin AI places quality and accuracy at the heart of its approach.
  • We are building the AI platform for the legal sector - a service that deeply understands every aspect of the legal function, from drafting contracts, researching case law to explaining legal concepts - our AI will help people tackle every legal task.

Appointment of Chief Business Officer

Retrieved on: 
Tuesday, December 19, 2023
Lynx, Bristol Myers Squibb, University of Oxford, Business, Imperial College London, Program director, AIM, Therapy, University, Business development, Genetics

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to announce the appointment of Dr Simon Bennett as Chief Business Officer of the Therapeutics Division.

Key Points: 
  • Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to announce the appointment of Dr Simon Bennett as Chief Business Officer of the Therapeutics Division.
  • He has worked with companies from large and mid-sized pharma such as Bristol-Myers-Squibb and Menarini Group to early stage biotechs, supporting business development and licensing activities in addition to being involved in all aspects of business and corporate development.
  • Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented:
    “As Chief Business Officer, Simon will work closely with the senior management team and lead commercial strategy and business development activities at this exciting period in the Company’s development as compelling clinical data emerges from the AVA6000 phase 1 trial.
  • Since then, Simon has worked as a consultant providing expert commercial and business development resources to a wide range of biopharmaceutical companies.

Enhanced Potential of Myricx’s NMT Inhibitor Payloads with Dual Senolytic and Cytotoxic Modes of Action as ADC Cancer Therapies

Retrieved on: 
Monday, November 27, 2023
Drug resistance, UKRI, Cellular senescence, Metastasis, Nature Cell Biology, Protein, Medicine, ICS, Research, Chemical biology, Imperial College London, Spacecraft, COPI, CRUK, NMT, ARF1, Cancer, GSK, Notifiable disease, Laboratory, Inflammation, Cell, Phenotype, Medical school, Data, ADC, Francis Crick Institute

Senescent, or so called ‘zombie’ cells, can have deleterious effects on tissue function as they are persistent and secrete many proteins.

Key Points: 
  • Senescent, or so called ‘zombie’ cells, can have deleterious effects on tissue function as they are persistent and secrete many proteins.
  • Small-molecule drugs that selectively eliminate senescent cells, known as senolytics, provide a promising novel strategy for treating multiple diseases, including cancer, fibrotic diseases, and age-related conditions.
  • Overall, the study demonstrated that senescent cells rely on a hyperactive secretory apparatus and that this secretory phenotype is dependent on NMT and inhibiting NMT kills senescent cells.
  • Combined with the cytotoxic effect of NMTis, the senolytic mechanism has the potential to induce deeper and more durable responses in treating tumours than purely cytotoxic payloads.

Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics

Retrieved on: 
Tuesday, November 21, 2023
Biology, WuXi Biologics, HER2, Imperial College London, NMT, Wuxi, Cancer, Patient, Development, ADC, Sofinnova, Francis Crick Institute, Fine chemical

Myricx intends to progress the ADC through preclinical and clinical development for difficult-to-treat solid tumours.

Key Points: 
  • Myricx intends to progress the ADC through preclinical and clinical development for difficult-to-treat solid tumours.
  • WuXi Bio will receive an upfront payment and will be eligible for development and commercialisation milestone payments, as well as royalties on net sales.
  • This is the second antibody license agreement that Myricx has entered into with a global company in the past few months as the Company builds out its pipeline of NMTi-ADCs.
  • Myricx CEO Dr Robin Carr said, “We are delighted to have reached this agreement with WuXi Bio, one of the top biologics CRDMOs globally.

March of Dimes Global Crowdsourcing Effort Yields Pair of Predictive Models for Preterm Birth

Retrieved on: 
Thursday, December 21, 2023
DREAM, Biology, Infant, Database, Stanford University, Pregnancy, Risk assessment, Risk, Infection, Division, Imperial College London, Data analysis, Research, Internal medicine, Wayne State University, Data, Health, Disease, Pediatrics, Preterm birth, Patent, University, Machine learning, OB/GYN, Dime, Collaboration, Bangladesh Technical Education Board, Manuscript, NIH, Sage Bionetworks, Bacteria, Vagina, UCSF, Data wrangling, Pharmaceutical industry

The 2023 March of Dimes Report Card shows that the U.S. preterm birth rate stands at 10.4%, a meager improvement from last year's historic high of 10.5%, the highest preterm birth rate in 10 years.

Key Points: 
  • The 2023 March of Dimes Report Card shows that the U.S. preterm birth rate stands at 10.4%, a meager improvement from last year's historic high of 10.5%, the highest preterm birth rate in 10 years.
  • Key to the predictive models is their ability to estimate a woman's risk for two types of preterm birth—one before 37 weeks and the other before 32 weeks.
  • The models' predictive power was strong: One predicted preterm birth with a 69% accuracy, and the other predicted early preterm birth with an 86% accuracy.
  • On Big Data Analysis and Preterm Birth Risk Prediction" episode on MODCAST, March of Dimes' research podcast, here .

Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors

Retrieved on: 
Wednesday, November 15, 2023
Aston, Engineering physics, NYSE, NMT, Francis Crick Institute, AstraZeneca, Spacecraft, Therapy, Biology, ADC, CSO, Patient, Sofinnova, MedImmune, Chemical engineering, Chris, Aston University, MBA, Drug discovery, University, Cancer, Imperial College London, IMD, Institution of Chemical Engineers, Knowledge, New York Stock Exchange, Fine chemical, Pharmaceutical industry

Dr Martin is a renowned biotech company founder, director and entrepreneur, and a pioneer and leader in the ADC space.

Key Points: 
  • Dr Martin is a renowned biotech company founder, director and entrepreneur, and a pioneer and leader in the ADC space.
  • Dr Martin was instrumental in co-founding ADC Therapeutics (NYSE: ADCT) in Jan 2012 and served as its CEO since inception until May 2022.
  • Alongside his role as Chairman of Myricx, he is also Chairman of the Board of Tokamak Energy Ltd, and Tagworks Pharmaceuticals BV, and a Director on the Board of Osivax SAS.
  • Dr Robin Carr, Myricx CEO and Board Director, said, “We are thrilled that Chris has joined our Board and taken on the role of Chairman.

DnaNudge secures FDA approval to deploy a Multiplex PCR platform for diagnosing four-in-one respiratory pathogens in Ghana

Retrieved on: 
Thursday, December 14, 2023
Health, FDA, Medical Devices, Infectious Diseases, Genetics, COVID-19, Biotechnology, Diabetic foot infection, FRS, DnaNudge, Vertically transmitted infection, Research, Urinary tract infection, DNA, RSV, Diabetic foot, Respiratory syncytial virus, Laureate, The Lancet, Clinical trial, Genomics, PCR, University, Medicine, Infection, Biomedicine, City, Medical research, University of Ghana, Imperial College London, RT, Partnership, RNA, Doctor of Philosophy, Quad, AI, SARS, Biomedical engineering, Life, TB, COVID, Vaccine, Medical device, Pharmaceutical industry

The lab-free, highly multiplexed sample-to-result test offers the capabilities of lab-based PCR diagnostics.

Key Points: 
  • The lab-free, highly multiplexed sample-to-result test offers the capabilities of lab-based PCR diagnostics.
  • Unlike the majority of other nucleic acid point-of-care tests based on isothermal amplification methods, the DnaNudge technology uses gold standard RT-PCR.
  • Testing samples can be collected via nasopharyngeal, nasal only or combined nose and throat swabs.
  • The unique lab-free nature of the DnaNudge system means that the test is ideal for use by healthcare professionals in any setting, including urban and rural environments.